PT2792662T - Compostos de morfinano - Google Patents

Compostos de morfinano

Info

Publication number
PT2792662T
PT2792662T PT141731901T PT14173190T PT2792662T PT 2792662 T PT2792662 T PT 2792662T PT 141731901 T PT141731901 T PT 141731901T PT 14173190 T PT14173190 T PT 14173190T PT 2792662 T PT2792662 T PT 2792662T
Authority
PT
Portugal
Prior art keywords
morphinan compounds
morphinan
compounds
Prior art date
Application number
PT141731901T
Other languages
English (en)
Inventor
Tung Roger
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of PT2792662T publication Critical patent/PT2792662T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Ecology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
PT141731901T 2007-05-01 2008-04-30 Compostos de morfinano PT2792662T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91513007P 2007-05-01 2007-05-01
US91666207P 2007-05-08 2007-05-08
US97604407P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
PT2792662T true PT2792662T (pt) 2016-07-07

Family

ID=51894365

Family Applications (5)

Application Number Title Priority Date Filing Date
PT202006334T PT3825306T (pt) 2007-05-01 2008-04-30 Compostos de morfinano
PT110007648T PT2357183E (pt) 2007-05-01 2008-04-30 Compostos de morfinano
PT121765440T PT2522668E (pt) 2007-05-01 2008-04-30 Compostos de morfinano
PT121764765T PT2522667E (pt) 2007-05-01 2008-04-30 Compostos de morfinano
PT141731901T PT2792662T (pt) 2007-05-01 2008-04-30 Compostos de morfinano

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PT202006334T PT3825306T (pt) 2007-05-01 2008-04-30 Compostos de morfinano
PT110007648T PT2357183E (pt) 2007-05-01 2008-04-30 Compostos de morfinano
PT121765440T PT2522668E (pt) 2007-05-01 2008-04-30 Compostos de morfinano
PT121764765T PT2522667E (pt) 2007-05-01 2008-04-30 Compostos de morfinano

Country Status (15)

Country Link
US (6) US9314440B2 (pt)
EP (5) EP3093290B1 (pt)
BR (1) BRPI0811478B8 (pt)
CA (3) CA2945581C (pt)
CY (1) CY1117826T1 (pt)
DK (4) DK3825306T3 (pt)
ES (5) ES2545617T3 (pt)
FI (1) FI3825306T3 (pt)
HK (5) HK1178889A1 (pt)
HR (5) HRP20230745T3 (pt)
HU (3) HUE025569T2 (pt)
LT (1) LT3825306T (pt)
PL (3) PL2357183T3 (pt)
PT (5) PT3825306T (pt)
SI (2) SI3825306T1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3825306T3 (da) 2007-05-01 2023-09-11 Sun Pharmaceutical Ind Inc Morphinanforbindelser
EP4183787A1 (en) * 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinan compounds
EP3193872A4 (en) * 2014-09-14 2018-02-28 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
CA2994169A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
WO2017020014A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
WO2017064876A1 (ja) 2015-10-14 2017-04-20 学校法人 久留米大学 グレリンを有効成分として含有するレット症候群（ｒｔｔ）の予防・治療剤
US11542481B2 (en) 2017-01-19 2023-01-03 Donald Danforth Plant Science Center Morphinan N-demethylase isolated from the methylobacterium thebainfresser and methods of use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US38115A (en) 1863-04-07 Improvement in turning edges of plates or metal sheets
GB713146A (en) 1951-10-18 1954-08-04 Roche Products Ltd Anti-cough agents comprising (ú½)-3-hydroxy-n-methyl-morphinane ethers and process for the manufacture thereof
US4316888A (en) 1980-04-15 1982-02-23 Nelson Research & Development Co. Method and composition of reducing pain
US4446140A (en) 1981-12-10 1984-05-01 Nelson Research & Development Company Method and composition for treating mouth pain
JPS6089474A (ja) 1983-10-20 1985-05-20 Toyo Pharma- Kk モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤
US4694010A (en) 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
US4898860A (en) 1985-08-16 1990-02-06 New York University Anticonvulsant composition and method
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5336980A (en) 1992-12-10 1994-08-09 Leopold Kostal Gmbh & Co. Apparatus and method for controlling a windshield wiping system
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
WO1995026325A2 (en) 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5863927A (en) 1994-09-22 1999-01-26 Center For Neurologic Study Dextromethorphan and an oxidase inhibitor for treating intractable conditions
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CH690817A5 (de) 1996-09-03 2001-01-31 Flachsmann Ag Emil Verfahren zur Herstellung eines stabilen, homogenen, von Folgeprodukten freien oder nahezu freien Extraktes.
CA2256897C (en) 1997-03-27 2006-10-03 Toray Industries, Inc. Morphinan derivatives and medical uses
US6884429B2 (en) 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
CA2318738A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
WO2001041707A2 (en) 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US6780871B2 (en) 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US20040087479A1 (en) 2001-04-30 2004-05-06 Sosnowski Robert E. Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases
US6583152B2 (en) 2001-04-30 2003-06-24 Dexgen Pharmaceuticals, Inc. Composition for reducing the risk or progression of cardiovascular diseases
MXPA03009971A (es) 2001-05-03 2004-02-12 Hoffmann La Roche FORMA DE DOSIFICACIoN FARMACEUTICA DE MESILATO DE NELFINAVIR AMORFO.
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
UA77234C2 (en) 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
EP1506174B1 (en) 2002-05-17 2015-09-30 Taiwanj Pharmaceuticals Co., Ltd. Use of naltrexone for treating kidney and liver damage
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
DE102004009445A1 (de) 2004-02-27 2005-09-29 Chemetall Gmbh Verfahren zur Herstellung von Alkyllithiumverbindungen und Aryllithiumverbindungen durch Reaktionsverfolgung mittels IR-Spektroskopie
KR100753984B1 (ko) 2004-05-14 2007-08-31 강원대학교산학협력단 우회전성 모르피난의 신경보호적 특성
JP2008514706A (ja) 2004-09-29 2008-05-08 コーディス・コーポレイション 安定非晶質ラパマイシン様化合物の薬学的投与形態
US20070191411A1 (en) 2004-10-07 2007-08-16 Smith Richard A Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor
US7114547B2 (en) 2005-01-11 2006-10-03 Sullivan Michael R Casting ring
AR054583A1 (es) 2005-07-26 2007-06-27 Altana Pharma Ag Pantoprazol isotopicamente sustituido
EP1910322B1 (en) 2005-07-29 2012-09-05 Concert Pharmaceuticals Inc. Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
AU2007285845A1 (en) 2006-08-16 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
EP2059241A1 (en) 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008097924A2 (en) 2007-02-05 2008-08-14 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MX370608B (es) * 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
DK3825306T3 (da) 2007-05-01 2023-09-11 Sun Pharmaceutical Ind Inc Morphinanforbindelser
EP2805950B1 (en) 2008-09-19 2017-11-08 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds
WO2010062692A1 (en) 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
JP6525419B2 (ja) 2015-01-15 2019-06-05 株式会社半導体エネルギー研究所 二次電池

Also Published As

Publication number Publication date
SI3825306T1 (sl) 2023-10-30
EP3357923A1 (en) 2018-08-08
ES2545617T3 (es) 2015-09-14
HRP20140903T1 (hr) 2014-11-21
US9314440B2 (en) 2016-04-19
DK2522668T3 (en) 2015-05-26
US20180327809A1 (en) 2018-11-15
EP3825306A1 (en) 2021-05-26
LT3825306T (lt) 2023-08-10
PT2522668E (pt) 2015-06-09
EP2792662A1 (en) 2014-10-22
HUE029782T2 (en) 2017-04-28
EP2357183B1 (en) 2015-07-01
US20210348208A1 (en) 2021-11-11
EP2792662B1 (en) 2016-04-06
ES2951028T3 (es) 2023-10-17
EP3093290B1 (en) 2018-01-24
ES2536984T3 (es) 2015-06-01
HK1155442A1 (en) 2012-05-18
EP3357923B1 (en) 2019-11-13
SI2792662T1 (sl) 2016-10-28
HRP20150848T1 (hr) 2015-09-25
HRP20230745T3 (hr) 2023-10-27
BRPI0811478B1 (pt) 2020-12-29
EP3825306B8 (en) 2023-08-02
PL3825306T3 (pl) 2023-09-11
CA3208128A1 (en) 2008-11-13
HUE063526T2 (hu) 2024-01-28
US20140329846A1 (en) 2014-11-06
EP2357183A1 (en) 2011-08-17
US20240093265A1 (en) 2024-03-21
HUE025569T2 (en) 2016-02-29
FI3825306T3 (fi) 2023-08-23
ES2523286T3 (es) 2014-11-24
HK1201058A1 (zh) 2015-08-21
US20170037449A1 (en) 2017-02-09
ES2577477T3 (es) 2016-07-15
CA3056205C (en) 2023-09-26
HK1259133A1 (zh) 2019-11-29
PT2522667E (pt) 2014-11-11
PT2357183E (pt) 2015-09-28
HK1178154A1 (en) 2013-09-06
EP3825306B1 (en) 2023-06-07
DK2357183T3 (en) 2015-09-07
CY1117826T1 (el) 2017-05-17
DK3825306T3 (da) 2023-09-11
CA2945581C (en) 2021-11-16
US11473123B2 (en) 2022-10-18
HRP20160521T8 (hr) 2016-10-07
PT3825306T (pt) 2023-07-24
EP3093290A1 (en) 2016-11-16
HRP20150809T1 (hr) 2016-02-12
US20240117407A1 (en) 2024-04-11
DK2792662T3 (da) 2016-07-25
PL2357183T3 (pl) 2015-12-31
BRPI0811478A8 (pt) 2019-10-15
BRPI0811478B8 (pt) 2021-05-25
US9868976B2 (en) 2018-01-16
PL2792662T3 (pl) 2016-10-31
HRP20160521T1 (hr) 2016-08-12
CA3056205A1 (en) 2008-11-13
CA2945581A1 (en) 2008-11-13
BRPI0811478A2 (pt) 2014-11-04
HK1178889A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
HK1154856A1 (en) Morphinan compounds
HK1165198A1 (en) Diarylhydantoin compounds
GB0704407D0 (en) Compounds
GB0704394D0 (en) Compounds
HK1259133A1 (zh) 嗎啡烷化合物
GB0705672D0 (en) Compounds
GB0706165D0 (en) Compounds
GB0706164D0 (en) Compounds
GB0703756D0 (en) Compounds
GB0701985D0 (en) Compounds
GB0701977D0 (en) Compounds
GB0701956D0 (en) Compounds
GB0701197D0 (en) Compounds
GB0701968D0 (en) Compounds
GB0701969D0 (en) Compounds
GB0701981D0 (en) Compounds
GB0700287D0 (en) Compounds
GB0700286D0 (en) Compounds
GB0703906D0 (en) Compounds
GB0701984D0 (en) Compounds
GB0705330D0 (en) Compounds
GB0700283D0 (en) Compounds
GB0700112D0 (en) Compounds
GB0705800D0 (en) Compounds
GB0701986D0 (en) Compounds